CP 81282
CP 81282 is a tripeptide aspartic protease inhibitor, with an IC50 of 1 nM against human renin and an IC50 of 11 nM against endopeptidase. CP 81282 is applicable to the research of hypertension.
For research use only. We do not sell to patients.
- CAS No.: 121584-61-0
- Formula: C32H47F2N5O6
- Molecular Weight:635.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
CP 81282 potently inhibits human plasma renin with an IC50 of 1 nM and endothiapepsin with an IC50 of 11 nM[1].
CP 81282 binds to endothiapepsin as a tetrahedral hydrate, forming specific hydrogen bonds with active-site aspartates 32 and 215, and adopts an extended conformation that interacts with additional enzyme residues[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 121584-61-0
-
Molecular Weight 635.74
-
Formula C32H47F2N5O6
-
SMILES
CNC(C(F)(C(C(NC(C(NC(C(CC1=CC=CC=C1)NC(N2CCOCC2)=O)=O)CCCC)=O)CC3CCCCC3)=O)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)